Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247061 | 0.86 | NPC1 (0.51) | NPC1RAB9ALMNAHDAC8HDAC6 | |
| SCHEMBL10247274 | 0.77 | HDAC8 (0.54) | HDAC8HDAC6CA1CA2ACHE | |
| SCHEMBL354884 | 0.77 | HDAC8 (0.54) | HDAC8HDAC6 | |
| SCHEMBL10246889 | 0.76 | CA1 (0.58) | HDAC8HDAC6CA1CA2ACHE | |
| SCHEMBL10246883 | 0.75 | HDAC8 (0.65) | NPC1RAB9AHDAC8HDAC6 | |
| SCHEMBL10246967 | 0.74 | CHRNA7 (0.53) | HDAC8HDAC6 | |
| SCHEMBL10247271 | 0.74 | HDAC8 (0.68) | NPC1RAB9AHDAC8HDAC6CA1 | |
| SCHEMBL356788 | 0.74 | HDAC6 (0.60) | NPC1RAB9AHDAC8HDAC6 | |
| SCHEMBL10246881 | 0.74 | HDAC8 (0.52) | HDAC8HDAC6 | |
| SCHEMBL10247042 | 0.74 | HDAC6 (0.57) | HDAC8HDAC6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | NPC1 2866/4885RAB9A 1801/4885LMNA 1529/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | NPC1 2958/4885RAB9A 1003/4885LMNA 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.